SUMMARY Vasodilator drugs activate neurohumoral forces that produce peripheral vasoconstriction and tachycardia and probably cause the rebound events observed upon abrupt withdrawal of therapy. To determine their role in limiting therapeutic vasodilator responses, these reactive forces were measured in 40 patients with severe chronic heart failure by quantifying the magnitude of rebound change (MRC) after nitroprusside withdrawal. Group 1 patients (n = 22), who had minimal reactive vasoconstriction (MRC 27%), showed marked hemodynamic effects with nitroprusside (4.5 ,g/kg/min) and isosorbide dinitrate (40 mg orally), associated with significant decreases in heart rate with both drugs (p < 0.001). Despite administration of the same doses of both drugs, group 2 patients (n = 18), who had marked rebound changes (MRC > 27%), showed significantly smaller changes in cardiac index, systemic vascular resistance and mean arterial pressure (p < 0.001), associated with no change or increases in heart rate. Rebound events were attenuated and the responses to nitroprusside and nitrates were enhanced in four patients in whom these drugs were readministered after pretreatment with i.v. phentolamine (0.3 mg/min). We conclude that activation of neurohumoral forces can limit the hemodynamic responses to vasodilator administration; this supports the use of combination therapy of direct-acting vasodilators and neurohumoral antagonists in selected patients with severe chronic heart failure.
ADMINISTRATION of peripheral vasodilator agents is of established value in the management of patients with severe chronic heart failure.1 2 However, recent studies have indicated that the response to vasodilator therapy varies. Although cardiac performance often improves substantially, many patients show little objective hemodynamic benefit, and some may have adverse cardiovascular reactions.3 7 These varied results may occasionally be due to differences in the doses of drugs,8"10 but factors in addition to direct drug-mediated vasodilation are probably important. 7 In normal and hypertensive subjects not in heart failure, nitroprusside not only produces direct peripheral vasodilation, but also activates counterposing mechanisms that cause peripheral vasoconstriction and tachycardia."-',' These counterposing forces become evident as rebound phenomena when, upon the abrupt cessation of nitroprusside, direct drugmediated vasodilation rapidly disappears, leaving the reactive forces unopposed.`' The rebound hemodynamic changes after the abrupt withdrawal of nitroprusside in patients with congestive heart failure suggest that similar reactive mechanisms underlie the responses to vasodilator therapy in such patients as well."' Given similar degrees of peripheral vasodilation, left ventricular chamber size is an important factor in the response to vasodilator therapy in patients with severe chronic heart failure. 7 However, what determines the magnitude of peripheral vasodilation in patients given similar d6ses of vasodilator drugs is not known. Marked activation of reactive vasoconstrictor forces can greatly limit the therapeutic hypotensive responses to vasodilator administration in hypertensive patients,"' 17 SO it is likely that these forces can also limit the magnitude of drug-induced peripheral vasodilation in patients with heart failure. To explore this question, we evaluated the degree of activation of vasoconstrictor forces by quantitative analysis of rebound hemodynamic changes after the abrupt withdrawal of nitroprusside in a large series of patients with severe heart failure who manifested differing responses to similar doses of vasodilator drugs.
Methods
We evaluated 45 patients, 35 men and 10 women, ages 40-83 years (mean 64 years). All had severe chronic congestive heart failure refractory to optimal conventional therapy with digitalis and diuretics. The etiology of heart failure was ischemic cardiomyopathy in 32 patients, idiopathic cardiomyopathy in five and advanced rheumatic valvular regurgitation in five (two with mitral regurgitation and three with aortic regurgitation); three patients had undergone aortic and/or mitral valve replacement more than 1 year before study. Diagnosis was based on clinical, electrocardiographic, echocardiographic and radioisotopic criteria and was confirmed by cardiac catheterization in 25 patients. The duration of heart failure ranged from 6 months to 8 years. Thirty-three patients were in normal sinus rhythm, seven had atrial fibrillation and five had ventricular pacemaker rhythm.
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All patients were studied during a period of relative clinical stability. No patient had sustained a myocardial infarction within 3 months or an episode of acute heart failure within 3 weeks before this study; no patient had received any vasodilator drug within 7 days. Bed rest was maintained and all medications were withheld for 12-24 hours before evaluation. Doses of digoxin and diuretics were continued unchanged throughout the period of study but were separated from the administration of vasodilator drugs by at least 12 hours.
Hemodynamic Measurements
After written, informed consent, right-heart catheterization was performed with a triple-lumen, flowdirected catheter to measure right atrial, pulmonary arterial and pulmonary capillary wedge pressures. Arterial cannulae were inserted into the radial artery in all patients to measure systemic pressures. Measurements were made with zero reference level at the midaxillary line with the patient supine. Left ventricular filling pressures (LVFPs) were measured as mean pulmonary capillary wedge pressure or pulmonary arterial diastolic pressure after its identity with wedge pressure was established. Thermodilution cardiac outputs (COs) were determined in triplicate with a bedside CO computer (Instrumentation Laboratories) using iced injectate. Heart rates (HRs) were derived from a continuously recorded ECG. Patients with LVFPs less than 20 mm Hg were excluded from the present study.
Drug Administration
The following hemodynamic variables were determined for at least 3 Twenty-four hours thereafter, the responses to nitroprusside and nitrate therapy were reevaluated in four patients, who were pretreated with a continuous infusion of phentolamine (0.3 mg/min). The infusion of phentolamine was begun 1 hour before and continued through the period of readministration of nitroprusside and isosorbide dinitrate, which were performed in a manner identical to the initial evaluation.
Statistical Analysis
Mean systemic and pulmonary arterial pressures were determined by electronic filtration. When analyzing changes in HR, the five patients with a permanent ventricular pacemaker rhythm were excluded; the seven patients with atrial fibrillation were included, however, and the HRs were determined as the average of three 20- Quantitative analysis of rebound events observed after nitroprusside withdrawal was performed as previously described.'5 Peak rebound was defined as the time when the maximal increase in SVR was observed after discontinuation of the drug. The magnitude of hemodynamic rebound changes was defined as the percentage increase in SVR at peak rebound (SVRr) above the pretreatment value (SVRI), where the magnitude of rebound change (MRC) = (SVRr -SVRI)/SVRI X 100. Quantification of MRC was taken to represent the degree of activation of arterial vasoconstrictor forces during vasodilator administration. Peak rebound could not be defined in the five patients who required reinstitution of nitroprusside because of severe rebound symptoms, so they were excluded from further analysis.
The responses to nitroprusside therapy were evaluated in the remaining 40 patients by comparing the hemodynamic variables at the maximal infusion rate of the drug (4.5 similar. Patients in groups 1 and 2 were simil respect to age and sex, the etiology of underlyin disease and the number of patients with auscu evidence of mitral regurgitation. The echo graphic end-diastolic dimension7 was similar two groups (67 ± 10 mm in group 1 and 62 ± 9 group 2), as were the pretreatment LVFP, MR} MAP. Only the control CI (1.57 in group 1 1/min/m2 in group 2, p < 0.001) and the contrn (2082 in group 1 vs 1618 dyn-sec-cm-" in group 0.05) differed significantly between the two ( fig. 1) LVFP  26  13  33  28  14  30  30  6  35  30  14  MAP  74  60  83  79  68  76  73  53  87  78  66  HR  77  77  87  83  79  81  90  96  95  95  90  SVR  1790  1294  2514  2253  1670  2097  1559  752  1904  1532 circulation is unclear. 13 [25] [26] [27] [28] [29] In either case, in patients with severe left ventricular failure, plasma catecholamines fail to increase and may even decrease with vasodilators;"'' 30 this is consistent with our observations that patients with a markedly reduced CI manifested little change or even decreases in HR despite significant decreases in systemic pressures during therapy and demonstrated mild rebound changes. Patients in our study with a mildly reduced CI, however, manifested reactions similar to those of normal and hypertensive subjects, which is consistent with experimental evidence that baroreceptor reflexes are only mildly attenuated in subjects in whom ventricular function is only mildly impaired. Alternatively, to explain the limited response to vasodilator drugs in patients with near-normal levels of SVR, other investigators have hypothesized that the ability to dilate vascular beds must be proportional to the degree of basal vasoconstriction.5' 12 Although this concept of vascular sensitivity may account for the varied effects of agents with specific sites of action (i.e., the pronounced effects of angiotensin converting-enzyme inhibition in high-renin states),42 it does not explain the differing responses in patients treated with direct-acting vasodilator drugs. Zelis et al. reported that despite the high levels of peripheral resistance, the peripheral vessels in patients with severe congestive heart failure are less responsive to vasodilator stimuli than they are in patients with compensated heart failure or in normal subjects.43 Furthermore, the concept of vascular sensitivity does not explain the occurrence of rebound withdrawal phenomena in patients treated with direct-acting agents. Instead, our present observations suggest that when similar quantities of such drugs are administered, differences in the degree of peripheral vasodilation are due to difference in the magnitude of the circulatory reaction to drug administration rather than different sensitivity to the direct vascular effects of these agents. This is consistent with our finding that the MRC was a better predictor of the magnitude of peripheral vasodilation achieved during drug administration than was the calculated SVR before treatment.
Our observations must be interpreted cautiously. We quantified only the rebound changes in SVR and thus examined only the arterial component of druginduced vasoconstrictor forces. It is likely, however, that during vasodilator administration, venoconstriction occurs as well and may accordingly influence the magnitude of changes in venous return and ventricular filling pressures observed during therapy. Our observation that the reduction in ventricular filling pressures with nitroprusside and nitrates was similar in patients with marked differences in the magnitude of rebound arterial vasoconstriction suggests that venoconstrictor forces may operate independently; we did not, however, perform peripheral plethysmographic studies during nitroprusside withdrawal in an attempt to quantify rebound venoconstrictor phenomena. More important, the degree of activation of arterial vasoconstrictor forces determines only the magnitude of the decrease in SVR that is achieved with a given dose of a vasodilator drug and not necessarily the manner in which the reduction in SVR is translated into an improvement in cardiac performance. We have shown that whether peripheral vasodilation results in a drop in blood pressure with minimal changes in CO or produces marked increases in stroke work with minimal hypotension is likely to be determined by myocardial factors (ventricular chamber size or systolic wall stress) rather than peripheral mechanisms.7 If such myocardial factors are to be evaluated independently, drug doses need to be titrated to achieve comparable decreases in peripheral resistance in the patients being studied. This would require smaller doses of a vasodilator drug in patients with minimal reactive forces than in patients with intact neurohumoral responses.
Finally, although our observations demonstrate the importance of vasoconstrictor forces in limiting acute vasodilator responses, their role in modifying the effects of long-term vasodilator therapy is not known. Several studies, however, suggest a role of major importance. Pagani et al. showed that delayed peripheral vasoconstriction is responsible for the rapid attenuation of acute responses to nitroprusside.1 Similarly, activation of the sympathetic and reninangiotensin systems may explain the attenuated responses to repeated doses of captopril, nitrates and prazosin."52 Whether, with time, these counterposing forces remained unchanged, increase in magnitude and result in complete loss of drug effect, or whether the mechanisms themselves are attenuated and permit restoration of drug action remains to be determined."3 Nevertheless, the concept of delayed activation of counterposing vasoconstrictor forces may explain why the acute responses to a vasodilator agent may not necessarily predict its long-term hemodynamic or clinical benefits;48' l,1,4, a similar phenomena may account in part for the lack of correlation of plasma drug levels and hemodynamic effects.47 9 0 Of potentially greater importance, however, the preliminary data in the present study indicate that blockade of these forces may enhance the acute responses to vasodilator drugs and thus could prevent drug tolerance or restore the effectiveness of drugs to which tolerance has developed; further work, however, is needed to confirm and expand these findings. Combination therapy of direct-acting vasodilators with drugs that interfere with the activity of the sympathetic nervous or renin-angiotensin systems may therefore be a more effective approach to the treatment of heart failure than the use of single-agent therapy;32 the superiority of this approach has already been established in selected patient populations in the treatment of systemic hypertension. 16 17 In conclusion, the present study indicates that many of the reported differences in the responses to vasodilator therapy are due to varying degrees of activation of counterposing vasoconstrictor forces, which can limit and modify the hemodynamic benefit. Such mechanisms may be responsible for the limited effectiveness of vasodilators in patients with milder degrees of heart failure, for the tachycardia in some treated subjects, for the rapid attenuation of initial beneficial responses and for the rebound changes which occur upon the abrupt withdrawal of therapy. Concomitant use of drugs that block the sympathetic nervous or renin-angiotensin systems may enhance the effects of direct-acting vasodilator agents and reduce the potential for drug tolerance and rebound clinical events.
